

Curriculum Vitae
C. Noah Israel, MD, FACC

Practice

2009-Present Tyler Cardiac and Endovascular Center
1769 Troup Hwy, Tyler, Texas

2005-Present Vein Center of East Texas

1982-Present Cardiovascular Associates of East Texas

Affiliation

1982-Present CAET - Research
1761 Troup Hwy, Tyler, Texas

1/1/13-4/26/13 TAD Clinical Research
1741 Troup Hwy, Tyler, Texas

Education

Cardiology Fellowship

1980-1982 Baystate Medical Center, Springfield, Massachusetts

Post-Doctoral Training

1977-1980 Internal Medicine Residency, Danbury Hospital, Danbury, Connecticut

1976-1977 Fifth Pathway-Rotating Clinical Clerkship, Nassau County Medical Center,
Stony Brook, New York

Academic Degree

1972-1976 University Autonoma of Guadalajara
Doctor of Medicine

1968-1972 York College of the City University of New York
BA in Biology

Board Certification

Dec. 2006 International Board of Heart Rhythm Examiners, Formerly NASPE Exam #0049

Nov. 1983 Diplomate American Board of Cardiovascular Disease

Sept. 1981 Diplomate American Board of Internal Medicine

Licensure

Aug. 1982 Texas State Board of Medical Examiners #G2396

Hospital Appointments

Trinity Mother Frances Hospital, Tyler, Texas

East Texas Medical Center, Tyler, Texas

East Texas Medical Center, Pittsburg, Texas

East Texas Medical Center, Jacksonville, Texas

East Texas Medical Center, Carthage, Texas

East Texas Medical Center, Quitman, Texas

Nacogdoches Memorial Hospital, Tyler, Texas

Administrative Appointments

2014 Co-Director of Cardiac Cath Lab
Trinity Mother Frances, Tyler, Texas

1998-2003 Director of Cardiovascular Rehabilitation
East Texas Medical Center, Tyler, Texas

1996-2003 Medical Director Cardiovascular Services
East Texas Medical Center, Tyler, Texas

1989-1994 Ad Hoc Cardiovascular Task Force Committee
East Texas Medical Center, Tyler, Texas

1986-1988 Chairman Cardio Pulmonary Section
East Texas Medical Center, Tyler, Texas

1983-1996 Director of Cardiovascular Rehabilitation
Trinity Mother Frances Hospital, Tyler, Texas

Professional Speaker

2010-Present Boehringer Ingelheim – Pradaxa

Professional Societies and Other Memberships – Past and Present

Fellow American College of Cardiology

American College of Phlebology

State Board Member, American Heart Association, Texas Affiliate – Past

Smith County Medical Society

Texas medical Association

American Heart Association, Smith County Chapter, Past President

Texas Medical Foundation

American Society of Nuclear Medicine

Research

Co-Investigator – ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Co-Investigator – AVERT - “A prospective, randomized, parallel group, multi-center clinical evaluation, to assess the AVERT system device for CM volume reduction and incidence of CIN”.

Co-Investigator – CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (Iorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

Co-Investigator – DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Primary Investigator - GLORIA –AF - Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients with Atrial Fibrillation.

Primary Investigator - ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Primary Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

Primary Investigator - RECORD-AF - **RE**gistry on **C**ardiac rhythm dis**ORD**ers: an international, observational, prospective survey assessing the control of **A**trial **F**ibrillation”

Primary Investigator – RE-LY - **R**andomized **E**valuation of **L**ong term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.

Primary Investigator – ASPEN Study – “AF Suppression Pacing to Prevent First Episode of Atrial Fibrillation in High Risk Patients” – Study.

Primary Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.

Primary Investigator - GUSTO-Pilot Trial - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries.

Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries.

Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; angiography substudy.

Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; two year follow up substudy.

Primary Investigator - GUSTO IV AMI (Protocol CO116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of. ReoPro™ (ABCIXIMAB) in combination with reduced dose Retavase™/Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.

Principal Investigator – ER-TIMI 19 – A Phase IV, Open-Label Trial of Prehospital Administration of Retavase® for ST elevation MI – the Early Retavase® (ER) – TIMI 19 Trial

Primary Investigator - MK-383 Protocol #008-00; A randomized, double-blind study of MK-383 in patients with unstable angina pectoris concomitantly receiving Heparin Collaborative Clinical Research, Inc.

Primary Investigator - PACT trial (Plasminogen-Activator Angioplasty Compatibility Trial) A randomized, double-blind placebo controlled study assessing clinical efficacy of bolus infusion TPA to placebo in acute MI patients with rescue angioplasty.

Primary Investigator - IMDUR (isosorbide mononitrate) P94-070 Phase IV Patient Acceptability Program. A study comparing the efficacy, safety and ease of use of three FDA-approved formulation; IMDUR, ISDN, and ISMO. The study design assesses if patients with stable angina pectoris benefit – in terms of fewer anginal attacks, increased exercise tolerance, simplicity and convenience of use.

Principal Investigator – OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparison of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension

Principal Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Principal Investigator – EPHEBUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.

Investigator - ULTRA study- Ventricular Automatic Capture assessment Study.

Investigator – TRENDS- A prospective, non-randomized, multi-center trial in subjects implanted with a commercially available Medtronic implantable pulse generator (IPG), implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. The primary purpose of the trial is to determine if the device trending data are indicators of clinical outcomes in subjects with atrial tachyarrhythmias.

Investigator- MASTER-- Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients.
Investigator – AWARE - Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias.

Investigator – FiB07 – A randomized, double-blind study comparing the patency rate and safety of two different preparations of Intravenous Eminase (BRL 26921) in patients with acute myocardial infarction.

Investigator – The rapid administration of alteplase (rt-Pa) myocardial infarction (RAAMI) Trial: Increased efficiency of 100 mg of rt-PA with modified dosing.

Investigator – A multi-center, prospective, randomized, placebo-controlled trial of Activase and Heparin in patients with unstable angina (UNSA)

Investigator – An Anglo-Scandinavian North American multi-center trial of Alteplase (rt-PA) therapy in patients who present with acute myocardial infarction six to twenty-four hours following onset of symptoms. (LATE)- Late Assessment of Thrombolytic Efficacy.

Investigator – ISIS-3 – The third international study of infarct survival.

Investigator – Timi-IIIb – Thrombolysis in myocardial ischemia and unstable angina study. Study of the effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction.

Co-Investigator - ANALYZE ST - Monitoring to Detect ACS Events in ICD Patients (Analyze ST)

Co-Investigator - LSS 4 SITE - The Longitudinal Surveillance Study of the 4-SITE Lead/Header System

Co-Investigator - INGEVITY - Active Fixation and Passive Fixation Pace/Sense Lead Clinical Study

Co-Investigator - ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Co-Investigator - SUMMIT - HZC113782 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

Co-Investigator - DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator - AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator - EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator - EUCLID -A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator - OPTIMUM Registry - A prospective, outcome-oriented registry of patients implanted with SJM Optim™ leads. This registry evaluated the chronic performance of the market-released SJM Cardiac Rhythm Management (CRM) leads with Optim™ insulation material.

Co-Investigator - RATE Registry – Registry of AT/AF Episodes in the CRM Device Population.

Co-Investigator - PLATO Study - A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS).

Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Co-Investigator – VISION 305 Study - “Vasodilator Induced Stress In Concordance with Adenosine” A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.

Co-Investigator - APEX-AMI Study - “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.

Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).

Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).

Co-Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.

Co-Investigator - ACCOMPLISH- A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.

Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System.

Co-Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST- segment elevation.

Co-Investigator - TMR012-A. A Single-Blind Randomized Study of the Safety and Effectiveness of Percutaneous Transluminal Myocardial Revascularization (PTMR) Performed with the Eclipse Holmium Laser as an Adjunct to Percutaneous Coronary Intervention.

Co-Investigator - Coumadin, Aspirin and Reinfarction Study; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.

Co-Investigator - Coumadin, Aspirin and Reinfarction EKG Substudy; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.

Co-Investigator – NRMI – National Registry for Myocardial Infarction.

Co-Investigator - PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation - 2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.

Co-Investigator - BioSlide Catheter SCIMED

Co-Investigator - Paragon B Trial: A randomized, double-blind, placebo-controlled study of Lamifiban (RO44-9883) in patients with unstable angina/non-Q wave myocardial infarction.

Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.

Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-Investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label, community-based clinical practice study of Niaspan in patients with hyperlipidemia.

Co-Investigator - CardioGenesis Transmyocardial Revascularization (TMR) System: To evaluate the safety and efficacy of the CardioGenesis TMR System when used for TMR performed as an adjunct to CABG in patients with angina resulting from coronary artery disease which is only partially treatable by CABG.

Co-Investigator - ATLAS Trial (Aspirin TicLid vs Anticoagulation for Stents) - George Washington University, Cardiovascular Research Institute.

Co-Investigator - DESTINI (Doppler Endpoint Stenting International Investigation): A multicenter randomized prospective evaluation of clinical outcome comparing primary stenting and a new practice pattern of optimal balloon angioplasty guided by quantitative angiography and intracoronary Doppler.

Co-Investigator – MICCAT (MICardis Community Access Trial) An Phase IV – Open label evaluation of the effectiveness of Micardis® (telmisartan) on blood pressure control and quality of life in patients with essential hypertension.

Co-Investigator – GUSTO IV ACS – A phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ReoPro™, given as a bolus followed by a 24- or 48-hour infusion, for the treatment of acute coronary syndrome without ST-segment elevation.

Co-Investigator – STEP AMI – An Open Study, with Blinded Endpoint Assessment, to Assess the Safety, Tolerability and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as both Monotherapy and Adjunct to Activase in Patients with ST-elevation Myocardial Infarction.

Co-Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.

Co-Investigator - REPLACE II - A Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Part 2: REPLACE-2 (TMC-BIV-01-03)

Co-Investigator – SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS).
Aventis Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532

Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: Cordarone® I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US

Co-Investigator – CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease. To Monitor inflammatory markers

Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglePhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.

Co-Investigator – Otsuka Protocol 21-98-214-01 CASTLE “ A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease”.

Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy “AMIHOT” Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.

Co-Investigator – AGENT 3 - A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina

Co-Investigator – Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System

Co-Investigator - RESOLUTE US: “A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of *De Novo* Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm.”

Co-Investigator - Taxus Libertē “A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Libertē-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen”

Co-Investigator - TAO: "A randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy"

Co-Investigator - VISTA-16 Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes

Co-Investigator - IMPROVE IT A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial

Co-Investigator - St. Jude Medical Product Longevity and Performance (SCORE) Registry

Co-Investigator - ST Monitoring to Detect ACS Events in ICD Patients (Analyze ST)

Co-Investigator - Quick FLEX Model 1258T Left Heart Pacing Lead Post Approval Study

Co-Investigator - ENDEAVOR SVS Registry: "A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single *De novo* Lesions in Small Diameter Native Coronary Arteries

Co-Investigator - TRACER "A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome"

Co-Investigator – Paradigm - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.